| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mobility Limitation | 20 | 2020 | 219 | 3.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 30 | 2018 | 1424 | 2.540 |
Why?
|
| Hypoglycemic Agents | 16 | 2016 | 181 | 2.520 |
Why?
|
| Anxiety Disorders | 8 | 2020 | 77 | 2.290 |
Why?
|
| Exercise | 26 | 2024 | 663 | 2.190 |
Why?
|
| Hypoglycemia | 11 | 2018 | 45 | 2.060 |
Why?
|
| Aged | 119 | 2024 | 10288 | 1.980 |
Why?
|
| Aging | 22 | 2024 | 941 | 1.970 |
Why?
|
| Telephone | 5 | 2017 | 59 | 1.780 |
Why?
|
| Life Style | 19 | 2020 | 407 | 1.660 |
Why?
|
| Walking | 17 | 2020 | 208 | 1.480 |
Why?
|
| Disabled Persons | 12 | 2023 | 105 | 1.480 |
Why?
|
| Aged, 80 and over | 64 | 2024 | 3988 | 1.470 |
Why?
|
| Female | 122 | 2024 | 19859 | 1.400 |
Why?
|
| Male | 119 | 2024 | 19091 | 1.390 |
Why?
|
| Disability Evaluation | 21 | 2019 | 238 | 1.350 |
Why?
|
| Humans | 139 | 2024 | 31836 | 1.230 |
Why?
|
| Geriatric Assessment | 19 | 2019 | 390 | 1.190 |
Why?
|
| Cognition | 16 | 2022 | 551 | 1.170 |
Why?
|
| Activities of Daily Living | 13 | 2022 | 257 | 1.120 |
Why?
|
| Diabetic Angiopathies | 6 | 2013 | 143 | 1.000 |
Why?
|
| Gait | 7 | 2023 | 140 | 0.940 |
Why?
|
| Quality of Life | 10 | 2023 | 924 | 0.930 |
Why?
|
| Brain | 10 | 2023 | 949 | 0.860 |
Why?
|
| Exercise Therapy | 10 | 2018 | 268 | 0.830 |
Why?
|
| Resistance Training | 7 | 2024 | 79 | 0.820 |
Why?
|
| Middle Aged | 52 | 2022 | 11824 | 0.810 |
Why?
|
| Health Education | 16 | 2018 | 157 | 0.810 |
Why?
|
| Rural Population | 4 | 2017 | 273 | 0.800 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2024 | 1323 | 0.770 |
Why?
|
| Blood Glucose | 11 | 2018 | 491 | 0.750 |
Why?
|
| Weight Loss | 8 | 2019 | 465 | 0.720 |
Why?
|
| Muscle Strength | 10 | 2024 | 159 | 0.700 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2018 | 27 | 0.690 |
Why?
|
| Randomized Controlled Trials as Topic | 13 | 2020 | 504 | 0.660 |
Why?
|
| Health Status | 7 | 2023 | 397 | 0.650 |
Why?
|
| Single-Blind Method | 17 | 2020 | 201 | 0.640 |
Why?
|
| Hyperglycemia | 3 | 2016 | 84 | 0.640 |
Why?
|
| Independent Living | 7 | 2023 | 99 | 0.630 |
Why?
|
| Accidental Falls | 4 | 2020 | 221 | 0.620 |
Why?
|
| Obesity | 12 | 2022 | 1158 | 0.620 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2016 | 54 | 0.610 |
Why?
|
| Physical Fitness | 8 | 2019 | 131 | 0.600 |
Why?
|
| Psychotherapy, Group | 1 | 2017 | 17 | 0.580 |
Why?
|
| Cognition Disorders | 8 | 2017 | 384 | 0.570 |
Why?
|
| Depression | 7 | 2017 | 442 | 0.550 |
Why?
|
| Motor Activity | 8 | 2018 | 325 | 0.550 |
Why?
|
| Pilot Projects | 16 | 2019 | 537 | 0.530 |
Why?
|
| Cardiovascular Diseases | 13 | 2017 | 1122 | 0.520 |
Why?
|
| Postural Balance | 7 | 2024 | 182 | 0.510 |
Why?
|
| Mental Health Services | 1 | 2015 | 28 | 0.500 |
Why?
|
| Risk Factors | 21 | 2020 | 3851 | 0.500 |
Why?
|
| Long-Term Care | 3 | 2019 | 25 | 0.500 |
Why?
|
| Myocardial Infarction | 3 | 2015 | 480 | 0.480 |
Why?
|
| Treatment Outcome | 18 | 2022 | 3294 | 0.470 |
Why?
|
| Telemedicine | 1 | 2015 | 99 | 0.470 |
Why?
|
| Cross-Sectional Studies | 15 | 2023 | 1527 | 0.470 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 168 | 0.440 |
Why?
|
| Hospitalization | 8 | 2022 | 463 | 0.430 |
Why?
|
| Body Mass Index | 13 | 2024 | 916 | 0.430 |
Why?
|
| Diabetes Mellitus, Type 1 | 6 | 2018 | 251 | 0.420 |
Why?
|
| Diabetic Nephropathies | 6 | 2013 | 224 | 0.420 |
Why?
|
| Thiazolidinediones | 4 | 2013 | 47 | 0.400 |
Why?
|
| Age Factors | 10 | 2019 | 1187 | 0.390 |
Why?
|
| Health Promotion | 6 | 2017 | 246 | 0.380 |
Why?
|
| Yoga | 2 | 2022 | 50 | 0.370 |
Why?
|
| Insulin | 4 | 2018 | 366 | 0.360 |
Why?
|
| Risk Assessment | 5 | 2020 | 1431 | 0.360 |
Why?
|
| United States | 17 | 2019 | 3925 | 0.350 |
Why?
|
| Rotator Cuff | 4 | 2018 | 72 | 0.340 |
Why?
|
| Muscle, Skeletal | 5 | 2015 | 513 | 0.340 |
Why?
|
| Medicare | 3 | 2019 | 206 | 0.330 |
Why?
|
| Longitudinal Studies | 8 | 2024 | 771 | 0.330 |
Why?
|
| Follow-Up Studies | 15 | 2019 | 2271 | 0.320 |
Why?
|
| Arthralgia | 1 | 2008 | 33 | 0.320 |
Why?
|
| Anxiety | 4 | 2022 | 188 | 0.320 |
Why?
|
| Interleukin-6 | 3 | 2019 | 251 | 0.310 |
Why?
|
| Health Expenditures | 2 | 2018 | 66 | 0.310 |
Why?
|
| Critical Illness | 2 | 2019 | 87 | 0.300 |
Why?
|
| Hospitals | 2 | 2018 | 98 | 0.300 |
Why?
|
| Adult | 20 | 2024 | 9327 | 0.300 |
Why?
|
| Body Composition | 9 | 2024 | 388 | 0.300 |
Why?
|
| Knee Joint | 1 | 2008 | 142 | 0.290 |
Why?
|
| Movement | 2 | 2016 | 50 | 0.280 |
Why?
|
| Antihypertensive Agents | 5 | 2017 | 351 | 0.280 |
Why?
|
| Shoulder Joint | 3 | 2018 | 126 | 0.270 |
Why?
|
| Pain | 4 | 2022 | 287 | 0.270 |
Why?
|
| Motor Skills Disorders | 2 | 2017 | 7 | 0.270 |
Why?
|
| Frail Elderly | 2 | 2018 | 68 | 0.270 |
Why?
|
| Patient Compliance | 3 | 2018 | 224 | 0.260 |
Why?
|
| Hand Strength | 5 | 2018 | 100 | 0.260 |
Why?
|
| Vestibular Diseases | 1 | 2005 | 5 | 0.260 |
Why?
|
| Posture | 1 | 2005 | 54 | 0.250 |
Why?
|
| Physical Examination | 1 | 2005 | 92 | 0.240 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2005 | 58 | 0.240 |
Why?
|
| Social Support | 2 | 2016 | 180 | 0.240 |
Why?
|
| Research Design | 7 | 2024 | 310 | 0.230 |
Why?
|
| Contrast Sensitivity | 1 | 2023 | 4 | 0.230 |
Why?
|
| Hypertension | 7 | 2017 | 956 | 0.230 |
Why?
|
| Neuropsychological Tests | 8 | 2017 | 370 | 0.230 |
Why?
|
| Macular Degeneration | 1 | 2023 | 22 | 0.220 |
Why?
|
| Caloric Restriction | 3 | 2019 | 95 | 0.220 |
Why?
|
| Muscles | 1 | 2023 | 62 | 0.220 |
Why?
|
| Leukoencephalopathies | 1 | 2023 | 12 | 0.220 |
Why?
|
| Adaptation, Psychological | 3 | 2015 | 136 | 0.220 |
Why?
|
| Wrist | 1 | 2022 | 48 | 0.210 |
Why?
|
| Fee-for-Service Plans | 2 | 2019 | 12 | 0.210 |
Why?
|
| Losartan | 2 | 2019 | 64 | 0.210 |
Why?
|
| Mortality | 2 | 2015 | 124 | 0.210 |
Why?
|
| Attitude | 1 | 2002 | 40 | 0.210 |
Why?
|
| Ankle | 1 | 2002 | 29 | 0.210 |
Why?
|
| Inflammation | 3 | 2018 | 540 | 0.200 |
Why?
|
| Knee | 1 | 2002 | 33 | 0.200 |
Why?
|
| Diabetic Retinopathy | 2 | 2014 | 65 | 0.200 |
Why?
|
| Severity of Illness Index | 6 | 2017 | 899 | 0.200 |
Why?
|
| Upper Extremity | 2 | 2012 | 57 | 0.200 |
Why?
|
| Patient Transfer | 2 | 2019 | 44 | 0.200 |
Why?
|
| Osteoarthritis | 1 | 2002 | 79 | 0.200 |
Why?
|
| Linear Models | 7 | 2019 | 449 | 0.190 |
Why?
|
| Adipose Tissue | 2 | 2015 | 345 | 0.190 |
Why?
|
| Fractures, Bone | 1 | 2022 | 144 | 0.180 |
Why?
|
| Patient Care Management | 1 | 2020 | 18 | 0.180 |
Why?
|
| Comorbidity | 5 | 2017 | 566 | 0.180 |
Why?
|
| Coronary Artery Disease | 4 | 2013 | 398 | 0.170 |
Why?
|
| Subacute Care | 1 | 2019 | 14 | 0.170 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 65 | 0.170 |
Why?
|
| Disease Progression | 8 | 2014 | 593 | 0.170 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2019 | 56 | 0.170 |
Why?
|
| Palliative Care | 1 | 2019 | 52 | 0.160 |
Why?
|
| Skilled Nursing Facilities | 1 | 2018 | 11 | 0.160 |
Why?
|
| Cohort Studies | 8 | 2017 | 1824 | 0.160 |
Why?
|
| Diet Therapy | 1 | 2018 | 15 | 0.160 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 756 | 0.160 |
Why?
|
| Insulin Infusion Systems | 1 | 2018 | 6 | 0.160 |
Why?
|
| Baltimore | 1 | 2018 | 50 | 0.160 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 98 | 0.150 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2010 | 151 | 0.150 |
Why?
|
| Nutritional Status | 1 | 2018 | 75 | 0.150 |
Why?
|
| Kidney | 3 | 2011 | 515 | 0.150 |
Why?
|
| Prospective Studies | 6 | 2018 | 2277 | 0.150 |
Why?
|
| Computer Simulation | 1 | 2018 | 220 | 0.150 |
Why?
|
| Osteoarthritis, Knee | 3 | 2003 | 90 | 0.150 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 104 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2018 | 92 | 0.140 |
Why?
|
| Diet, Reducing | 3 | 2016 | 102 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 144 | 0.140 |
Why?
|
| Prevalence | 3 | 2015 | 979 | 0.140 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2015 | 97 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 215 | 0.140 |
Why?
|
| Fibroblasts | 3 | 2009 | 112 | 0.140 |
Why?
|
| African Americans | 2 | 2017 | 1428 | 0.130 |
Why?
|
| Mechanical Phenomena | 1 | 2016 | 28 | 0.130 |
Why?
|
| Psychotherapy | 1 | 2015 | 19 | 0.130 |
Why?
|
| Factor Analysis, Statistical | 3 | 2010 | 76 | 0.130 |
Why?
|
| Preventive Health Services | 1 | 2016 | 44 | 0.130 |
Why?
|
| Double-Blind Method | 5 | 2019 | 523 | 0.130 |
Why?
|
| Obesity, Morbid | 1 | 2016 | 71 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 249 | 0.130 |
Why?
|
| Sleep | 1 | 2016 | 92 | 0.130 |
Why?
|
| Muscular Atrophy | 1 | 2015 | 70 | 0.130 |
Why?
|
| Time Factors | 7 | 2019 | 2146 | 0.130 |
Why?
|
| Shoulder | 1 | 2015 | 42 | 0.130 |
Why?
|
| Memory | 2 | 2014 | 190 | 0.120 |
Why?
|
| Ankle Brachial Index | 1 | 2015 | 38 | 0.120 |
Why?
|
| Isometric Contraction | 2 | 2012 | 23 | 0.120 |
Why?
|
| Skin | 3 | 2009 | 210 | 0.120 |
Why?
|
| Prognosis | 5 | 2019 | 1498 | 0.120 |
Why?
|
| Blood Pressure | 3 | 2014 | 843 | 0.120 |
Why?
|
| Health Surveys | 1 | 2015 | 196 | 0.120 |
Why?
|
| Atrophy | 1 | 2014 | 46 | 0.120 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2014 | 2 | 0.120 |
Why?
|
| Heart Rate | 1 | 2016 | 332 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2015 | 113 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 288 | 0.110 |
Why?
|
| Psychomotor Performance | 2 | 2011 | 99 | 0.110 |
Why?
|
| Pyruvaldehyde | 1 | 2013 | 1 | 0.110 |
Why?
|
| Attitude to Health | 1 | 2015 | 165 | 0.110 |
Why?
|
| Vitamin K 1 | 1 | 2013 | 11 | 0.110 |
Why?
|
| Organ Size | 4 | 2017 | 208 | 0.110 |
Why?
|
| Physical Endurance | 2 | 2014 | 35 | 0.110 |
Why?
|
| Hypercholesterolemia | 1 | 2014 | 69 | 0.110 |
Why?
|
| Exercise Tolerance | 3 | 2010 | 124 | 0.110 |
Why?
|
| Overweight | 4 | 2018 | 276 | 0.110 |
Why?
|
| Patient Selection | 1 | 2014 | 276 | 0.110 |
Why?
|
| Lipids | 1 | 2014 | 228 | 0.110 |
Why?
|
| Health Behavior | 3 | 2014 | 231 | 0.100 |
Why?
|
| Coronary Vessels | 1 | 2013 | 158 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2013 | 185 | 0.100 |
Why?
|
| Age Distribution | 2 | 2017 | 206 | 0.100 |
Why?
|
| Calcium | 1 | 2013 | 304 | 0.100 |
Why?
|
| Lower Extremity | 2 | 2016 | 100 | 0.100 |
Why?
|
| Diabetes Mellitus | 2 | 2011 | 409 | 0.090 |
Why?
|
| Acceleration | 2 | 2022 | 65 | 0.090 |
Why?
|
| Aviation | 1 | 2010 | 2 | 0.090 |
Why?
|
| Pennsylvania | 1 | 2010 | 83 | 0.090 |
Why?
|
| Range of Motion, Articular | 3 | 2016 | 187 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 89 | 0.090 |
Why?
|
| Macular Edema | 1 | 2010 | 17 | 0.090 |
Why?
|
| Young Adult | 4 | 2024 | 2603 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2011 | 103 | 0.090 |
Why?
|
| Cells | 1 | 2009 | 4 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 183 | 0.080 |
Why?
|
| Leg | 1 | 2009 | 66 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2019 | 3488 | 0.080 |
Why?
|
| Incidence | 3 | 2020 | 1192 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2009 | 70 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2009 | 103 | 0.080 |
Why?
|
| Markov Chains | 1 | 2008 | 29 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2019 | 148 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 105 | 0.080 |
Why?
|
| International Classification of Diseases | 1 | 2008 | 25 | 0.080 |
Why?
|
| European Continental Ancestry Group | 2 | 2014 | 1169 | 0.080 |
Why?
|
| Visual Acuity | 2 | 2023 | 73 | 0.080 |
Why?
|
| Personal Satisfaction | 1 | 2008 | 28 | 0.080 |
Why?
|
| Adolescent | 4 | 2024 | 3511 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2006 | 508 | 0.070 |
Why?
|
| Child | 3 | 2024 | 2425 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2013 | 767 | 0.070 |
Why?
|
| Glutathione Peroxidase | 1 | 2006 | 9 | 0.070 |
Why?
|
| Catalase | 1 | 2006 | 15 | 0.070 |
Why?
|
| Siblings | 1 | 2006 | 25 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 686 | 0.070 |
Why?
|
| Health Status Indicators | 2 | 2020 | 73 | 0.070 |
Why?
|
| Survival Rate | 2 | 2019 | 884 | 0.070 |
Why?
|
| Sex Factors | 2 | 2019 | 662 | 0.070 |
Why?
|
| Antioxidants | 1 | 2006 | 114 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2007 | 225 | 0.060 |
Why?
|
| Logistic Models | 2 | 2011 | 777 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2009 | 400 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2017 | 195 | 0.060 |
Why?
|
| Cause of Death | 2 | 2019 | 238 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 109 | 0.060 |
Why?
|
| Creatinine | 2 | 2017 | 195 | 0.060 |
Why?
|
| Attention | 1 | 2024 | 83 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 2 | 2017 | 305 | 0.060 |
Why?
|
| Alzheimer Disease | 1 | 2007 | 327 | 0.050 |
Why?
|
| Hip | 1 | 2022 | 14 | 0.050 |
Why?
|
| Nerve Net | 1 | 2024 | 123 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2015 | 895 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 73 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 589 | 0.050 |
Why?
|
| Amlodipine | 1 | 2002 | 13 | 0.050 |
Why?
|
| Personality Assessment | 1 | 2002 | 9 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2002 | 64 | 0.050 |
Why?
|
| Joints | 2 | 2012 | 13 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2002 | 48 | 0.050 |
Why?
|
| Likelihood Functions | 1 | 2002 | 48 | 0.050 |
Why?
|
| Weight Lifting | 1 | 2002 | 10 | 0.050 |
Why?
|
| Patient Dropouts | 1 | 2002 | 28 | 0.050 |
Why?
|
| Emotions | 1 | 2002 | 56 | 0.050 |
Why?
|
| Fatigue | 1 | 2022 | 84 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2002 | 75 | 0.050 |
Why?
|
| Risk Reduction Behavior | 2 | 2013 | 125 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 284 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2002 | 213 | 0.050 |
Why?
|
| Albuminuria | 2 | 2017 | 181 | 0.050 |
Why?
|
| Sarcopenia | 2 | 2012 | 62 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2009 | 764 | 0.050 |
Why?
|
| Probability | 2 | 2009 | 158 | 0.040 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2009 | 27 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 218 | 0.040 |
Why?
|
| Respiratory Function Tests | 2 | 2010 | 108 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2018 | 184 | 0.040 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2017 | 29 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2009 | 293 | 0.040 |
Why?
|
| Self Efficacy | 2 | 2008 | 78 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2017 | 79 | 0.040 |
Why?
|
| Pulse | 1 | 2016 | 10 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 33 | 0.030 |
Why?
|
| Rest | 1 | 2016 | 54 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 173 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 874 | 0.030 |
Why?
|
| Time | 1 | 2016 | 23 | 0.030 |
Why?
|
| Rotation | 1 | 2016 | 47 | 0.030 |
Why?
|
| Patient Education as Topic | 2 | 2012 | 271 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 2016 | 102 | 0.030 |
Why?
|
| Anthropometry | 1 | 2015 | 83 | 0.030 |
Why?
|
| Exercise Test | 1 | 2016 | 225 | 0.030 |
Why?
|
| Publication Bias | 1 | 2015 | 8 | 0.030 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2015 | 3 | 0.030 |
Why?
|
| Glutamate Decarboxylase | 1 | 2015 | 17 | 0.030 |
Why?
|
| C-Peptide | 1 | 2015 | 29 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 178 | 0.030 |
Why?
|
| Cation Transport Proteins | 1 | 2015 | 24 | 0.030 |
Why?
|
| Microcirculation | 1 | 2015 | 65 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2015 | 49 | 0.030 |
Why?
|
| Angina, Unstable | 1 | 2014 | 21 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2014 | 40 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2015 | 76 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2009 | 833 | 0.030 |
Why?
|
| Glomerular Basement Membrane | 1 | 2013 | 4 | 0.030 |
Why?
|
| Methionine | 1 | 2013 | 8 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 629 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2013 | 33 | 0.030 |
Why?
|
| Smoking | 1 | 2017 | 499 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 318 | 0.030 |
Why?
|
| African Continental Ancestry Group | 1 | 2014 | 363 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 420 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 113 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 227 | 0.030 |
Why?
|
| Imidazoles | 1 | 2013 | 91 | 0.030 |
Why?
|
| Muscle Stretching Exercises | 1 | 2012 | 6 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2013 | 166 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2014 | 191 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2013 | 173 | 0.030 |
Why?
|
| Age of Onset | 1 | 2012 | 93 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 28 | 0.020 |
Why?
|
| Cystatin C | 1 | 2011 | 31 | 0.020 |
Why?
|
| Intention | 1 | 2011 | 28 | 0.020 |
Why?
|
| Albumins | 1 | 2011 | 45 | 0.020 |
Why?
|
| Choristoma | 1 | 2011 | 16 | 0.020 |
Why?
|
| Thigh | 1 | 2011 | 41 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2011 | 46 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 495 | 0.020 |
Why?
|
| Abdominal Fat | 1 | 2011 | 49 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2011 | 137 | 0.020 |
Why?
|
| Subcutaneous Fat | 1 | 2011 | 47 | 0.020 |
Why?
|
| Ethnic Groups | 1 | 2013 | 476 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 297 | 0.020 |
Why?
|
| Ligands | 1 | 2010 | 80 | 0.020 |
Why?
|
| Models, Biological | 1 | 2012 | 391 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2010 | 54 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 298 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2009 | 24 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2009 | 35 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 161 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 470 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 461 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 35 | 0.020 |
Why?
|
| Body Weight | 1 | 2010 | 306 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2008 | 162 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 211 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 239 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 334 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 323 | 0.020 |
Why?
|
| Demography | 1 | 2007 | 110 | 0.020 |
Why?
|
| Psychometrics | 1 | 2008 | 136 | 0.020 |
Why?
|
| Risk Management | 1 | 2007 | 27 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 912 | 0.020 |
Why?
|
| Stroke | 1 | 2011 | 581 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2006 | 148 | 0.020 |
Why?
|
| Cytokines | 1 | 2006 | 259 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 727 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 291 | 0.010 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2002 | 1 | 0.010 |
Why?
|
| Glomerular Mesangium | 1 | 2002 | 2 | 0.010 |
Why?
|
| Thrombospondin 1 | 1 | 2002 | 7 | 0.010 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2002 | 9 | 0.010 |
Why?
|
| Proteinuria | 1 | 2002 | 59 | 0.010 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2002 | 50 | 0.010 |
Why?
|
| Coronary Restenosis | 1 | 2002 | 13 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 247 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 137 | 0.010 |
Why?
|
| Kidney Glomerulus | 1 | 2002 | 30 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 2002 | 148 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2002 | 351 | 0.010 |
Why?
|